Susquehanna International Group, LLP Sigilon Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$0.34 - $1.38 $14,767 - $59,940	43,435 Added 43.45%	143,400 $133,000
Q4 2022 Feb 14, 2023	SELL	$0.29 - $0.69 $4,357 - $10,367	-15,026 Reduced 13.07%	99,965 $34,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $0.86 $23,668 - $42,405	49,309 Added 75.07%	114,991 $58,000
Q2 2022 Aug 15, 2022	BUY	$0.74 - $1.64 $35,238 - $78,095	47,619 Added 263.63%	65,682 $55,000
Q1 2022 May 16, 2022	SELL	$1.24 - $3.03 $31,066 - $75,913	-25,054 Reduced 58.11%	18,063 $27,000
Q4 2021 Feb 14, 2022	BUY	$2.58 - $6.13 $48,491 - $115,213	18,795 Added 77.28%	43,117 $119,000
Q3 2021 Nov 15, 2021	BUY	$4.42 - $10.61 $107,503 - $258,056	24,322 New	24,322 $137,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.